and long-acting GLP-1 RAs, including exenatide once-weekly, liraglutide, albiglutide, dulaglutide, and semaglutide, known for providing more consistent glycemic control 48,49
For vomiting, tirzepatide posed the highest risk (relative risk 13.22), followed by semaglutide (4.21) and liraglutide (3.87)
Protein from lean sources also promotes GLP-1 release while helping maintain muscle massan important consideration for anyone working on their healthy weight goals
[6] [7] It is important to note that retatrutide is currently only available within approved clinical trials, where participants receive training from the research team before self-administering
Abstract Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes
Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes